Zevra Therapeutics (ZVRA) Stock Forecast & Price Target

Compare

890 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZVRA Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Zevra

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZVRA Stock 12 Month Forecast

Average Price Target

$22.43

▲(142.22%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Zevra Therapeutics in the last 3 months. The average price target is $22.43 with a high forecast of $25.00 and a low forecast of $19.00. The average price target represents a 142.22% change from the last price of $9.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","8.75":"$8.75","14.5":"$14.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8.75,14.5,20.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.64,8.975384615384614,10.31076923076923,11.646153846153846,12.981538461538461,14.316923076923077,15.65230769230769,16.987692307692306,18.323076923076922,19.658461538461538,20.993846153846153,22.32923076923077,23.664615384615384,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.64,8.777692307692307,9.915384615384614,11.053076923076922,12.19076923076923,13.328461538461537,14.466153846153844,15.603846153846153,16.74153846153846,17.87923076923077,19.016923076923074,20.154615384615383,21.29230769230769,{"y":22.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.64,8.513846153846153,9.387692307692307,10.26153846153846,11.135384615384615,12.009230769230768,12.883076923076922,13.756923076923076,14.63076923076923,15.504615384615384,16.378461538461536,17.252307692307692,18.126153846153844,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.16,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$22.43

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-2.81%

Downside

Reiterated

05/17/25

Zevra Therapeutics' overall score is primarily influenced by strong revenue growth but is hampered by significant profitability and leverage issues. Technical indicators show positive momentum, yet caution is advised due to potential overbought conditions. The valuation remains challenging with ongoing losses, and while the earnings call highlighted strategic progress, market penetration challenges persist.

Jason ButlerCitizens JMP

Citizens JMP

$19

Buy

105.18%

Upside

Reiterated

05/27/25

Zevra Therapeutics (ZVRA) Receives a Buy from Citizens JMP

Jason McCarthyMaxim Group

Maxim Group

$25

Buy

169.98%

Upside

Reiterated

05/15/25

Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance

Jonathan AschoffRoth MKM

Roth MKM

$21

Buy

126.78%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Flora Growth (NASDAQ: FLGC), Cardinal Health (NYSE: CAH) and Zevra Therapeutics (NASDAQ: ZVRA)

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$25

Buy

169.98%

Upside

Reiterated

05/13/25

Zevra Therapeutics (ZVRA) Receives a New Rating from Cantor Fitzgerald

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$25

Buy

169.98%

Upside

Reiterated

05/13/25

Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating

Oren LivnatH.C. Wainwright

H.C. Wainwright

$20

Buy

115.98%

Upside

Reiterated

03/13/25

Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position

Eddie HickmanGuggenheim

Guggenheim

$20→$22

Buy

137.58%

Upside

Reiterated

03/12/25

Zevra Therapeutics price target raised to $22 from $20 at GuggenheimZevra Therapeutics price target raised to $22 from $20 at Guggenheim

Louise ChenScotiabank

Scotiabank

―

Buy

―

Reiterated

06/10/24

Cantor Fitzgerald reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA)Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-2.81%

Downside

Reiterated

05/17/25

Jason ButlerCitizens JMP

Citizens JMP

$19

Buy

105.18%

Upside

Reiterated

05/27/25

Zevra Therapeutics (ZVRA) Receives a Buy from Citizens JMP

Jason McCarthyMaxim Group

Maxim Group

$25

Buy

169.98%

Upside

Reiterated

05/15/25

Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance

Jonathan AschoffRoth MKM

Roth MKM

$21

Buy

126.78%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Flora Growth (NASDAQ: FLGC), Cardinal Health (NYSE: CAH) and Zevra Therapeutics (NASDAQ: ZVRA)

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$25

Buy

169.98%

Upside

Reiterated

05/13/25

Zevra Therapeutics (ZVRA) Receives a New Rating from Cantor Fitzgerald

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$25

Buy

169.98%

Upside

Reiterated

05/13/25

Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating

Oren LivnatH.C. Wainwright

H.C. Wainwright

$20

Buy

115.98%

Upside

Reiterated

03/13/25

Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position

Eddie HickmanGuggenheim

Guggenheim

$20→$22

Buy

137.58%

Upside

Reiterated

03/12/25

Zevra Therapeutics price target raised to $22 from $20 at GuggenheimZevra Therapeutics price target raised to $22 from $20 at Guggenheim

Louise ChenScotiabank

Scotiabank

―

Buy

―

Reiterated

06/10/24

Cantor Fitzgerald reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA)Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zevra Therapeutics

1 Month

xxx

Success Rate

7/13 ratings generated profit

Average Return

+7.25%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +7.25% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+12.44%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +12.44% per trade.

1 Year

Jason McCarthyMaxim Group

Success Rate

13/13 ratings generated profit

Average Return

+34.01%

reiterated a buy rating 25 days ago

Copying Jason McCarthy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.01% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+46.60%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +46.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZVRA Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZVRA has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZVRA average Analyst price target in the past 3 months is 22.43.

Each month's total comprises the sum of three months' worth of ratings.

ZVRA Financial Forecast

ZVRA Earnings Forecast

Next quarter’s earnings estimate for ZVRA is -$0.07 with a range of -$0.12 to -$0.01. The previous quarter’s EPS was -$0.06. ZVRA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year ZVRA has Outperformed its overall industry.

ZVRA Sales Forecast

Next quarter’s sales forecast for ZVRA is $22.43M with a range of $20.60M to $24.30M. The previous quarter’s sales results were $20.40M. ZVRA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year ZVRA has Outperformed its overall industry.

ZVRA Stock Forecast FAQ

What is ZVRA’s average 12-month price target, according to analysts?

Based on analyst ratings, Zevra Therapeutics’s 12-month average price target is 22.43.

What is ZVRA’s upside potential, based on the analysts’ average price target?

Zevra Therapeutics has 142.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZVRA a Buy, Sell or Hold?

Zevra Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Zevra Therapeutics’s price target?

The average price target for Zevra Therapeutics is 22.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $19.00. The average price target represents 142.22% Increase from the current price of $9.26.

What do analysts say about Zevra Therapeutics?

Zevra Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ZVRA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zevra Therapeutics (ZVRA) Stock Forecast & Price Target

ZVRA Analyst Ratings

ZVRA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zevra Therapeutics

ZVRA Analyst Recommendation Trends

ZVRA Financial Forecast

ZVRA Earnings Forecast

ZVRA Sales Forecast

ZVRA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts